Developer docs
API playgroundTry for free, no card

Search company profiles

Khiron

Full company profile

uuid0005z48

Namestring
Khiron
Legal namestring
Khiron Life Sciences Corp
Websiteurl
khiron.ca
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Khiron Life Sciences Corp (TSX-V: KHRN) is a publicly traded medical cannabis company headquartered in Bogotá, Colombia, with operational reach across Colombia, Germany, the United Kingdom, Peru, Brazil, Canada, and Australia. Founded in 2012 and currently employing 101–250 staff, the company runs a vertically integrated model that combines clinical care, pharmaceutical manufacturing, and medical education. Its core delivery vehicle is the Zerenia clinic network, which applies an integrative medicine framework to prescribe medical cannabis, supported by the Doctor Zerenia telehealth sub-brand and the ILANS health services brand; an online physician education platform, Khiron Academy, trains healthcare professionals on cannabis prescription.

Underlying the clinical operation is a pharmaceutical product line marketed under the Khiron Med brand, distributed directly in Germany and the UK. In August 2022 Khiron acquired Pharmadrug Production GmbH, a German pharmaceutical manufacturer and distributor with a GMP-certified facility, giving the company direct supply chain control in Europe and access to pharmaceutical-grade medical cannabis production. Combined with low-cost Colombian cultivation (equatorial climate, volcanic soil, lower labor costs), this German GMP footprint allows Khiron to export cannabis oil and flower competitively into multiple international markets.

The business generates revenue across three streams: (i) pharmaceutical cannabis product sales through health centers and international distribution (hardware-style sales), (ii) clinical and health services revenue from Zerenia consultations and treatment programs (professional services), and (iii) revenue from the Khiron Academy education platform (recurring/subscription). Customer segments are split between individual patients seeking medical cannabis therapy at Zerenia clinics (primary segment) and healthcare professionals requiring training and prescription guidance (secondary). GTM is primarily enterprise field sales combined with a sales-led distribution model, with direct operations offices and pharmacovigilance support lines in each served market. The company has disclosed cumulative funding of roughly C$25–30M across rounds in 2018, 2021, 2022, and 2023, and reports persistent negative EBITDA through 2021, indicating an early-scale operator still building toward profitability.

Short descriptiontext

Khiron Life Sciences Corp is a publicly traded (TSX-V: KHRN) medical cannabis company operating Zerenia integrative-medicine clinics in Colombia, exporting pharmaceutical-grade cannabis products to seven countries, and training prescribers via Khiron Academy, with GMP manufacturing in Germany through its Pharmadrug Production GmbH subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBogotá, Colombia
HQ citystring
Bogotá
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis products, pharmaceutical cannabis manufacturing, integrative medicine clinics, cannabis patient treatment, medical cannabis education
Industry4 codes
1Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
CodeCRANAFAIPrimaryYes
2Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
CodeCRANAFAGPrimaryNo
3Medical Cannabis Delivery & Online Ordering
CodeCRANAGAGPrimaryNo
4Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders)
CodeCRANAHAGPrimaryNo
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Medical Cannabis Healthcare
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Cannabis Pharmaceutical Products
TypeHardware Sales
Description

Development and sale of high-quality pharmaceutical cannabis products through health center network and international distribution

khiron.ca
2Health Services
TypeProfessional Services
Description

Revenue from integrative medicine health centers (Zerenia clinics) providing patient consultations and treatment programs

khiron.ca
3Medical Education Programs
TypeSubscription Recurring
Description

Khiron Academy provides training and education for health professionals on medical cannabis prescription

khiron.ca
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Zerenia
Description

Health clinic brand offering integrative medicine and medical cannabis treatments

khiron.ca
+4 more records
Core offering1 text field

Khiron Life Sciences Corp develops, manufactures, and distributes pharmaceutical-grade medical cannabis products under the Khiron Med brand in Germany and the UK, while operating a network of integrative medicine health centers (Zerenia and Doctor Zerenia) that provide direct patient consultations and medical cannabis prescriptions in Colombia. The company also delivers medical cannabis education and training to healthcare professionals through Khiron Academy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Supply chain control in Germany enabling increased gross margins
+1 more record
Product overview1 text field

Khiron Life Sciences Corp is a pureplay health and wellbeing company focused on the global medical cannabis market. The company operates a platform-plus-brands model consisting of Khiron Med (its core medical cannabis product line), Khiron Academy (medical education platform), and several health center sub-brands including Zerenia clinics, Doctor Zerenia digital health services, and ILANS wellness services. The company also acquired Pharmadrug Production GmbH to establish a European pharmaceutical distribution hub with GMP-certified manufacturing capabilities.

Product and service6 records
1Khiron Med (Germany)
CategoryMedical Cannabis Products
Description

Pharmaceutical-grade medical cannabis product brand serving patients in the German market through GMP-certified manufacturing operations.

2Khiron Med (UK)
CategoryMedical Cannabis Products
Description

Medical cannabis product brand serving patients in the UK market through Khiron Med distribution.

3Khiron Academy
CategoryMedical Education
Description

Online medical education platform providing training programs, clinical cases, and real-life examples for health professionals on medical cannabis prescription and clinical applications.

4Zerenia Health Centers
CategoryHealthcare Services
Description

Network of integrative medicine health centers providing patient consultations, medical cannabis prescriptions, and ongoing treatment through the Patient Follow-up Program in Colombia.

5Doctor Zerenia
CategoryDigital Health Services
Description

Digital health service platform providing patients access to medical cannabis prescriptions and ongoing treatment monitoring.

6ILANS
CategoryHealthcare Services
Description

Health services brand providing integrative medicine and wellness services.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-02
Description

Khiron completed the acquisition of Pharmadrug Production GmbH, a German pharmaceutical manufacturer and distributor with GMP-certified facility. This acquisition establishes Khiron's European pharmaceutical distribution hub for medical cannabis and other products, providing direct control of supply chain in Germany and expanding the company's medical cannabis product portfolio with increased gross margins.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Colombian-based medical cannabis cultivator and exporter with GMP-certified operations serving international markets — directly comparable to Khiron's Colombia-to-international export model.

TypeDirect peer
Description

Canadian-listed cannabis pharmaceutical company with significant Colombian operations and a focus on medical cannabis products — overlapping with Khiron's pharma-grade cannabis and Latin American footprint.

3Flora Growth
TypeDirect peer
Description

Colombian-headquartered cannabis cultivator and consumer products company — directly comparable geography and export orientation to Khiron's core Latin American operation.

TypeDirect peer
Description

Canadian medical and recreational cannabis producer with international medical cannabis distribution — comparable product mix and cross-border medical export strategy to Khiron Med.

TypeDirect peer
Description

US multi-state cannabis operator with a strong focus on medical cannabis retail and wholesale brands — comparable medical-cannabis-first orientation and brand-led strategy to Khiron.

TypeEmerging player
Description

Vertically integrated hemp-derived CBD wellness company selling through health and wellness channels — comparable wellness/medical-cannabis-adjacent positioning, though focused on hemp-derived rather than pharmaceutical-grade cannabis.

TypeBroad incumbent
Description

Large global cannabis company with medical cannabis operations in Germany, Portugal and Canada — competes with Khiron in European medical cannabis distribution and GMP-certified supply.

TypeBroad incumbent
Description

Major diversified cannabis company with international medical cannabis platforms including Germany — overlaps with Khiron's medical export model and German distribution ambitions.

TypeBroad incumbent
Description

Canadian cannabis producer with established European medical cannabis distribution through Aurora Europe — comparable international medical export footprint to Khiron.

TypeBroad incumbent
Description

Global cannabis company with medical cannabis operations in multiple jurisdictions including Israel and Germany — competes broadly with Khiron in international medical cannabis markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Khiron

Medical Cannabis Healthcarekhiron.ca

Khiron Life Sciences Corp is a publicly traded (TSX-V: KHRN) medical cannabis company operating Zerenia integrative-medicine clinics in Colombia, exporting pharmaceutical-grade cannabis products to seven countries, and training prescribers via Khiron Academy, with GMP manufacturing in Germany through its Pharmadrug Production GmbH subsidiary.

What Khiron does

Khiron Life Sciences Corp (TSX-V: KHRN) is a publicly traded medical cannabis company headquartered in Bogotá, Colombia, with operational reach across Colombia, Germany, the United Kingdom, Peru, Brazil, Canada, and Australia. Founded in 2012 and currently employing 101–250 staff, the company runs a vertically integrated model that combines clinical care, pharmaceutical manufacturing, and medical education. Its core delivery vehicle is the Zerenia clinic network, which applies an integrative medicine framework to prescribe medical cannabis, supported by the Doctor Zerenia telehealth sub-brand and the ILANS health services brand; an online physician education platform, Khiron Academy, trains healthcare professionals on cannabis prescription.

Underlying the clinical operation is a pharmaceutical product line marketed under the Khiron Med brand, distributed directly in Germany and the UK. In August 2022 Khiron acquired Pharmadrug Production GmbH, a German pharmaceutical manufacturer and distributor with a GMP-certified facility, giving the company direct supply chain control in Europe and access to pharmaceutical-grade medical cannabis production. Combined with low-cost Colombian cultivation (equatorial climate, volcanic soil, lower labor costs), this German GMP footprint allows Khiron to export cannabis oil and flower competitively into multiple international markets.

The business generates revenue across three streams: (i) pharmaceutical cannabis product sales through health centers and international distribution (hardware-style sales), (ii) clinical and health services revenue from Zerenia consultations and treatment programs (professional services), and (iii) revenue from the Khiron Academy education platform (recurring/subscription). Customer segments are split between individual patients seeking medical cannabis therapy at Zerenia clinics (primary segment) and healthcare professionals requiring training and prescription guidance (secondary). GTM is primarily enterprise field sales combined with a sales-led distribution model, with direct operations offices and pharmacovigilance support lines in each served market. The company has disclosed cumulative funding of roughly C$25–30M across rounds in 2018, 2021, 2022, and 2023, and reports persistent negative EBITDA through 2021, indicating an early-scale operator still building toward profitability.

Khiron firmographics

Firmographics
Name
Khiron
Legal name
Khiron Life Sciences Corp
Website
https://khiron.ca
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Khiron Life Sciences Corp is a publicly traded (TSX-V: KHRN) medical cannabis company operating Zerenia integrative-medicine clinics in Colombia, exporting pharmaceutical-grade cannabis products to seven countries, and training prescribers via Khiron Academy, with GMP manufacturing in Germany through its Pharmadrug Production GmbH subsidiary.
Ownership category
akta.pro rank

Khiron industry classification

Industry
Product category
Medical Cannabis Healthcare
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
akta.pro secondary industries
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG), Medical Cannabis Delivery & Online Ordering (CRANAGAG), Cannabis Accessories & Smoke Shops (Pipes, Papers, Grinders) (CRANAHAG)

Keywords

  • Medical cannabis products
  • Pharmaceutical cannabis manufacturing
  • Integrative medicine clinics
  • Cannabis patient treatment
  • Medical cannabis education

Where Khiron is headquartered

Location

Headquarters

HQ city
Bogotá
HQ country
Colombia
HQ region
Latin America

Offices6 records

Markets served

Khiron business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Cannabis Pharmaceutical Products: Development and sale of high-quality pharmaceutical cannabis products through health center network and international distribution
  2. Health Services: Revenue from integrative medicine health centers (Zerenia clinics) providing patient consultations and treatment programs
  3. Medical Education Programs: Khiron Academy provides training and education for health professionals on medical cannabis prescription

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Khiron product offering

Product offering

Core offering

Khiron Life Sciences Corp develops, manufactures, and distributes pharmaceutical-grade medical cannabis products under the Khiron Med brand in Germany and the UK, while operating a network of integrative medicine health centers (Zerenia and Doctor Zerenia) that provide direct patient consultations and medical cannabis prescriptions in Colombia. The company also delivers medical cannabis education and training to healthcare professionals through Khiron Academy.

Product overview

Khiron Life Sciences Corp is a pureplay health and wellbeing company focused on the global medical cannabis market. The company operates a platform-plus-brands model consisting of Khiron Med (its core medical cannabis product line), Khiron Academy (medical education platform), and several health center sub-brands including Zerenia clinics, Doctor Zerenia digital health services, and ILANS wellness services. The company also acquired Pharmadrug Production GmbH to establish a European pharmaceutical distribution hub with GMP-certified manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Zerenia: Health clinic brand offering integrative medicine and medical cannabis treatments
  • Doctor Zerenia
  • Ilans
  • Khiron Med (Germany)
  • Khiron Med (UK)

Products and services

  • Khiron Med (Germany) Pharmaceutical-grade medical cannabis product brand serving patients in the German market through GMP-certified manufacturing operations.
  • Khiron Med (UK) Medical cannabis product brand serving patients in the UK market through Khiron Med distribution.
  • Khiron Academy Online medical education platform providing training programs, clinical cases, and real-life examples for health professionals on medical cannabis prescription and clinical applications.
  • Zerenia Health Centers Network of integrative medicine health centers providing patient consultations, medical cannabis prescriptions, and ongoing treatment through the Patient Follow-up Program in Colombia.
  • Doctor Zerenia Digital health service platform providing patients access to medical cannabis prescriptions and ongoing treatment monitoring.
  • ILANS Health services brand providing integrative medicine and wellness services.

Quantifiable outcome

  • Supply chain control in Germany enabling increased gross margins
  • +1 more outcomes

Companies that use Khiron

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Khiron technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Khiron partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pharmadrug Production GmbHcoreStrategic or Co-development Partner · 2 August 2022Khiron completed the acquisition of Pharmadrug Production GmbH, a German pharmaceutical manufacturer and distributor with GMP-certified facility. This acquisition establishes Khiron's European pharmaceutical distribution hub for medical cannabis and other products, providing direct control of supply chain in Germany and expanding the company's medical cannabis product portfolio with increased gross margins.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Khiron competitors and assessment

Company assessment

Direct peers

  • Clever Leaves: Colombian-based medical cannabis cultivator and exporter with GMP-certified operations serving international markets — directly comparable to Khiron's Colombia-to-international export model.
  • Avicanna: Canadian-listed cannabis pharmaceutical company with significant Colombian operations and a focus on medical cannabis products — overlapping with Khiron's pharma-grade cannabis and Latin American footprint.
  • Flora Growth: Colombian-headquartered cannabis cultivator and consumer products company — directly comparable geography and export orientation to Khiron's core Latin American operation.
  • OrganiGram Holdings: Canadian medical and recreational cannabis producer with international medical cannabis distribution — comparable product mix and cross-border medical export strategy to Khiron Med.
  • Cresco Labs: US multi-state cannabis operator with a strong focus on medical cannabis retail and wholesale brands — comparable medical-cannabis-first orientation and brand-led strategy to Khiron.

Emerging players

  • Charlotte's Web Holdings: Vertically integrated hemp-derived CBD wellness company selling through health and wellness channels — comparable wellness/medical-cannabis-adjacent positioning, though focused on hemp-derived rather than pharmaceutical-grade cannabis.

Broad incumbents

  • Tilray Brands: Large global cannabis company with medical cannabis operations in Germany, Portugal and Canada — competes with Khiron in European medical cannabis distribution and GMP-certified supply.
  • Canopy Growth: Major diversified cannabis company with international medical cannabis platforms including Germany — overlaps with Khiron's medical export model and German distribution ambitions.
  • Aurora Cannabis: Canadian cannabis producer with established European medical cannabis distribution through Aurora Europe — comparable international medical export footprint to Khiron.
  • Cronos Group: Global cannabis company with medical cannabis operations in multiple jurisdictions including Israel and Germany — competes broadly with Khiron in international medical cannabis markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Khiron social profiles

Digital presence

Khiron compliance and trust

Trust signal

Compliance1 record

Khiron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Khiron leadership team

Management profile

Number of profiles

Profiles2 records

Khiron subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Khiron funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Khiron M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Khiron

What does Khiron do?

Khiron Life Sciences Corp develops, manufactures, and distributes pharmaceutical-grade medical cannabis products under the Khiron Med brand in Germany and the UK, while operating a network of integrative medicine health centers (Zerenia and Doctor Zerenia) that provide direct patient consultations and medical cannabis prescriptions in Colombia. The company also delivers medical cannabis education and training to healthcare professionals through Khiron Academy.

Is Khiron a public or private company?

Khiron is a public company. It is classified as public and is currently operating.

When was Khiron founded?

Khiron was founded in 2012. It employs 101 to 250 people.

Where is Khiron based?

Khiron is headquartered in Bogotá, Colombia, in the Latin America region.

How does Khiron make money?

Three revenue lines are on record. Medical Cannabis Pharmaceutical Products are the primary driver. The others are health Services and medical Education Programs.

Who are Khiron's main competitors?

Direct peers on record are Clever Leaves, Avicanna, Flora Growth, OrganiGram Holdings and Cresco Labs. Charlotte's Web Holdings is listed as an emerging player. Broad incumbents are Tilray Brands, Canopy Growth, Aurora Cannabis and Cronos Group.

Does Khiron have an API?

No public API is recorded for Khiron.

What industry is Khiron in?

Khiron's product category is Medical Cannabis Healthcare. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail). Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RespectmyregionCannabis in Colombia Is Entering A New Green ChapterColombia has evolved from criminalizing cannabis to establishing a regulated medical cannabis industry since legalizing it in 2016 under Law 1787, with over 300 licensed companies now cultivating and processing cannabis for export. The country's equatorial location provides year-round sunlight, volcanic soil, and lower labor costs, making it one of the most efficient cannabis-producing regions globally, with exports nearly doubling between 2023 and 2024. Key companies including PharmaCielo, Khiron Life Sciences, and Clever Leaves are shipping cannabis oil and flower to Canada, Germany, Brazil, and Australia, while recreational cannabis remains illegal though a 2024 legalization bill came one vote short in the Senate.NewswireKHIRON LIFE SCIENCES ANNOUNCES SIZING OF MARKETED OFFERING OF UNITSKhiron Life Sciences Corp. announced the sizing of a marketed public offering to issue up to 12,000,000 units at C$0.05 per unit, raising aggregate gross proceeds of up to C$600,000. The company will also amend the terms of approximately 30.7 million common share purchase warrants to reduce their exercise price and add an acceleration clause, subject to regulatory approval. Canaccord Genuity Corp. is acting as the agent and sole bookrunner for the offering, which is expected to close around April 4, 2023.Khiron Life Sciences Corp.Khiron closes revolving credit facility with Financing Company in ColombiaKhiron Life Sciences Corp. has closed a CAD 580,000 unsecured revolving credit facility with a private financing company in Colombia for its subsidiary ZereniaTM Colombia. The 12-month facility became effective on February 10, 2023, providing non-dilutive working capital to support the company's operations and growth.PR NewswireKhiron begins dispensation of insurance-covered prescriptions in ColombiaKhiron Life Sciences Corp. has begun dispensing medical cannabis to patients through its Zerenia clinic network in Colombia following the government's approval of insurance coverage for prescriptions effective January 1, 2023. This development allows patients to access funded medication under a new mandate that integrates medical cannabis into the national healthcare system. The move expands Khiron's operational reach in Colombia, where it is the leading medical cannabis clinic provider.PR NewswireKhiron Life Sciences Reports Third Quarter 2022 Financial ResultsKhiron Life Sciences reported its third quarter 2022 financial results, showing a 24% decrease in revenues mainly due to reduced medical cannabis sales in Colombia and a 141% increase in European revenues driven by the UK. The company had an adjusted EBITDA loss of $2.8 million and managed to expand sales of cannabis products into Brazil, Germany, Switzerland, and the UK.PR NewswireKhiron to Host Third Quarter 2022 Conference Call on November 30, 2022Khiron Life Sciences Corp. announced it will host a conference call on November 30, 2022 at 11:00 a.m. ET to discuss its third quarter 2022 financial results for the quarter ended September 30, 2022. The full financial results will be released via press release prior to the call and made available on the Company's SEDAR profile. The call will feature CEO Alvaro Torres, CFO Helen Bellwood, and President of Khiron Europe Franziska Katterbach.PR NewswireKhiron begins sales in Switzerland and expands its medical cannabis portfolio in Germany and the United KingdomKhiron Life Sciences Corp. has entered the Swiss medical cannabis market with initial sales of two new flower products, KHIRON Gelato 19/1 and KHIRON Caramel 5/7, marking its first market entry in the Alpine Republic. The company simultaneously expanded its European footprint by initiating sales of three exclusive products in the UK (marking the 1-year anniversary of Zerenia™ Clinics UK) and preparing to launch seven medical cannabis SKUs in Germany following import approvals from German regulators. Khiron completed its acquisition of EU GMP-certified Pharmadrug GmbH in Germany in August 2022, enabling the distribution hub that underpins this multi-market expansion.PR NewswireKhiron Life Sciences Reports Second Quarter 2022 Financial ResultsKhiron Life Sciences Corp. reported Q2 2022 financial results with revenues of $4.5 million, up 60% year-over-year, and first-half revenues of $9.1 million, up 62% year-over-year. The company achieved its lowest-ever Adjusted EBITDA loss of ($2.3) million while maintaining a 76% gross margin in its medical cannabis segment, which now represents 58% of total revenues. Key strategic actions included the acquisition of Pharmadrug GmbH in Germany to establish a European distribution hub and the opening of the first Zerenia clinic in Rio de Janeiro, Brazil.PR NewswireKhiron to Host Second Quarter 2022 Conference Call on August 29, 2022Khiron Life Sciences Corp. announced it will host a conference call on August 29, 2022 at 10:00 a.m. Eastern Time to discuss the company's financial results for the second quarter ended June 30, 2022. The financial results will be released via press release prior to the call and made available on the company's SEDAR profile. Khiron is a medical cannabis company with operations in Latin America and Europe, led by CEO Alvaro Torres and CFO Helen Bellwood.PR NewswireLíder em Cannabis medicinal Khiron abre a primeira Clínica Zerenia™ do BrasilKhiron Life Sciences Corp., a global medical cannabis company, has opened the first Zerenia™ clinic in Brazil, located in Ipanema, Rio de Janeiro, offering in-person consultations and telemedicine services with capacity for approximately 23,000 patient consultations per year and over 13 doctors. The expansion into Brazil follows Khiron's proven clinic model already deployed in Colombia, Peru, and the UK, with the company leveraging its strategic alliances with medical associations such as CANNAB and distributors such as TAIMIN to support the new facility. Brazil represents the largest medical cannabis market in Latin America with over 210 million people, and Khiron plans to launch additional THC cannabis products in the country in autumn.